The Newsroom

Investigations  /  07.27.2020

Investigation of Acer Therapeutics, Inc.

You Have Legal Options

Shareholder Class Action Against Acer Therapeutics Inc. (ACER) Survives Motion to Dismiss

Acer misrepresented that a conversation it had with the U.S. Food and Drug Administration regarding its drug candidate EDVISO.  Acer claimed publicly that “the FDA agreed that additional clinical development is not needed” for the drug.  Acer went on to raise almost $59 million in two offerings based on this information.  However, contrary to Acer’s public comments, the FDA had not approved the new drug application for EDVISO.  In June 2019, when Acer revealed that the FDA needed it to “conduct an adequate and well-controlled trial” to determine EDVISO’s effects in patients, Acer’s stock price fell $15.16 per share, or over 75%, to close at $4.12 per share. On June 16, 2020, U.S. District Court Judge Gregory H. Woods denied in part Acer’s motion to dismiss plaintiffs’ claims, stating that plaintiffs had plausibly alleged securities fraud claims. On July 21, 202, Judge Woods subsequently denied Defendants’ motion to reconsider his decision, paving the way for litigation to proceed.

  • If you would like more information about your rights and potential remedies please send us a message. 

  • Please Note: Neither the submission to nor the receipt of information by Robbins LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.


How can we help you?

CONTACT US TODAY | 1 800 350 6003 or [email protected]

Tell us your concerns